Publications by authors named "A Tuba Karagulle Kendi"
Article Synopsis
- * In a study conducted at Mayo Clinic, 273 patients were analyzed, revealing that those with liver metastasis received an average of 3 treatment cycles and had a lower response rate in prostate-specific antigen (PSA) reduction compared to patients without liver metastasis (30.23% vs. 49.77%).
- * The research utilized real-world clinical data and statistical methods to compare patient outcomes based on the presence of liver metastasis, highlighting disparities in treatment responses and survival rates.
Radioligand therapies such as [Lu] Lu-PSMA-617 have gained significant momentum in cancer treatment after clinical trials and multicenter studies demonstrated their safety and efficacy. As these innovative treatments become more widespread, rare and unique clinical manifestations are expected to be observed. In this report, we describe a case with metastatic castration-resistant prostate cancer (mCRPC) and peripancreatic lymph node metastases who developed acute pancreatitis following [Lu] Lu-PSMA-617 therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the low tumor doses achieved in non-prostate cancers treated with [Lu]Lu-PSMA radioligand, using a case of renal cell carcinoma as an example.
- Despite high uptake of the imaging agent [Ga]Ga-PSMA-11, treatment with [Lu]Lu-PSMA-I&T resulted in low radiation doses to tumors (0.2-0.5 Gy) and no observable treatment effect.
- The researchers suggest that the ineffective targeting may be due to PSMA receptors being located on new blood vessels rather than on tumor cells, leading to rapid washout; they propose using a radionuclide with a shorter half-life to improve treatment efficacy.
Article Synopsis
- - Optimal management of metastatic castration-resistant prostate cancer (mCRPC) is complicated by new treatments like [Lu]Lu-PSMA-617, requiring careful monitoring of adverse events (AEs) and adherence to radiation safety protocols.
- - The authors emphasize the importance of educating healthcare professionals on AEs (e.g., fatigue, dry mouth) and radiation safety to improve patient management during PSMA-targeted radiopharmaceutical therapy (RPT).
- - Effective patient counseling and multidisciplinary collaboration among oncologists and nuclear medicine teams are crucial for safe treatment delivery and addressing challenges like urinary incontinence.
Article Synopsis
- The gastrin-releasing peptide receptor (GRPr) is being studied as a potential diagnostic and therapeutic target for various cancers, particularly in detecting intra-prostatic prostate cancer (PCa) lesions using [Ga] Ga-GRPr PET imaging.
- A systematic review analyzed data from 9 studies with 291 patients, finding that [Ga] Ga-GRPr PET imaging had detection rates of 87.09% for overall patients and 89.01% for those with Gleason scores of 7 or higher, while per-lesion detection rates were 78.54%.
- The detection rate for multiparametric MRI (mpMRI) was slightly higher at 91.85%, but the difference compared to [Ga